Y-mAbs Therapeutics (YMAB) - Rentabilitas operasi

Simbol resmi perusahaan Y-mAbs Corp (YMAB)

Y-mAbs Therapeutics (YMAB) is developing radioimmunotherapy for rare pediatric tumors, expanding its presence across Asia and Europe. However, reliance on a single product and the complexities of global scaling create profitability risks. The operational efficiency trend clearly demonstrates these processes, and the current metric has settled at -31.20. Business resilience is based on patent protection and the regulatory approval of new indications.

YMAB - Tingkat bathi operasi Y-mAbs Therapeutics Inc ing rentang 04.07.2022 - 27.09.2025

Y-mAbs Therapeutics - rincian analitis lan metrik utama (YMAB)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:YMAB, YmAbs
Produk dadi Y-mAbs Corp

Y-mAbs Therapeutics (YMAB) is investing significant resources into developing antibodies for pediatric oncology in collaboration with Memorial Sloan Kettering. By analyzing the ratio of operating profit to revenue, an investor assesses the efficiency of cost management within the core business. This metric reveals the portion of profit remaining after operating expenses are paid, prior to accounting for financial obligations. The indicator's trend captures the company's ability to scale development without a disproportionate increase in costs, which determines the long-term fundamental stability of the business valuation.

Analisis pesaing Y-mAbs Therapeutics

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|AURA (Aura Biosciences Inc) - Margin operasi|Rentabilitas dodolan operasi candeltx.com CADL|Margin operasi ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Tingkat bathi operasi|Rentabilitas operasi Actuate Therapeutics, Inc. ACTU|citiusonc.com - Rentabilitas operasi|TuHURA Biosciences Inc. - Margin operasi|TARA - Margin operasi|FATE (Fate Therapeutics) - Margin dodolan operasi|Margin dodolan operasi Aadi Bioscience, Inc.|Margin dodolan operasi TCRX|Rentabilitas operasi CSBR|Margin operasi XBIT|Rentabilitas kegiatan operasi CEL-SCI Corp.|Rentabilitas operasi ostherapies.com OSTX|RADX: Rentabilitas dodolan miturut bathi operasi|ARTV: Margin dodolan operasi|ANL (Adlai Nortye) - Rentabilitas dodolan miturut bathi operasi|Veru (VERU) - Rentabilitas operasi|Margin dodolan operasi Tempest Therapeutics Inc|Rentabilitas operasi Xilio Therapeutics|Rentabilitas dodolan miturut bathi operasi RENB (Renovaro Inc.)|Rentabilitas operasi Mural Oncology PLC (MURA)|Margin operasi Kairos Pharma (KAPA)|Rentabilitas operasi onkuretherapeutics.com OKUR|GDTC: Rentabilitas dodolan miturut bathi operasi|CRIS: Margin dodolan operasi|apollomicsinc.com (APLM) - Margin dodolan operasi|THAR: Margin operasi|Margin dodolan operasi Advanced Biomed Inc.|Margin dodolan operasi GNPX|Rentabilitas dodolan miturut bathi operasi CLDI (Calidi Biotherapeutics)|Margin operasi SBFM|Xenetic Biosciences, Inc. - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Salarius Pharmaceuticals SLRX|Margin operasi purple-biotech.com PPBT|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi